MVA-BN Brachyury: Phase I started

Bavarian Nordic began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1, 2 or 4 injections of 2x10 8 infectious units of subcutaneous MVA-BN Brachyury once monthly for 3 months in up to...